

**EGF THERAMED HEALTH CORP.**

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1. Name and Address**

EGF Theramed Health Corp. (the “**Company**”)  
5728 East Boulevard  
Vancouver, British Columbia, V6M 4M4

**Item 2. Date of Material Change**

April 22, 2020 and April 29, 2020.

**Item 3. News Release**

The Company issued news releases on April 22, April 29, and April 30, 2020 relating to the material change, which were disseminated through Stockwatch and subsequently filed on SEDAR.

**Item 4. Summary of Material Change**

The Company completed a non-brokered private placement (the “**Offering**”) through the issuance of 3,400,000 units (each, a “**Unit**”) of the Company at a price of \$0.50 per Unit for gross proceeds of CAD\$1,700,000. Each Unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of \$0.75 for a period of eighteen (18) months from issuance. The Offering closed in two tranches, with the first tranche of 2,860,000 Units closing on April 22, 2020 and the second tranche of 540,000 Units closing on April 29, 2020.

**Item 5. Full Description of Material Change**

See attached news releases.

**Item 6. Reliance on Subsection 7.1(2) of National Instrument 51-102**

Not applicable. This report is not being filed on a confidential basis.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

The following executive officer of the Company is knowledgeable about the material change and this report:

David Bentil, Chief Executive Officer  
Telephone: (778) 559-3939

**Item 9. Date of Report**

May 6, 2020.



## **EGF THERAMED HEALTH CORP. CLOSES PRIVATE PLACEMENT OF \$1,430,000**

**Vancouver, B.C., April 22, 2020** – EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “Company”)

EGF Theramed Health Corp. has closed its previously announced (dated April 13, 2020) non-brokered private placement.

The Company has closed on 2,860,000 units at a price of \$0.50 per unit for gross proceeds of \$1,430,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire an additional common share of the Company at a price of \$0.75 for a period of 18 months from the closing of the offering.

In connection with the private placement, the Company has paid cash finders’ fee of \$29,100 and issued 57,000 finder’s warrants at an exercise price of \$0.75 expiring 18 months from the date of issue. All securities issued in the offering are subject to a hold period expiring on August 23, 2020.

The net proceeds from the non-brokered private placement are intended to be used for working capital and acquisitions.

The company has increased its efforts in researching psilocybin and psychedelic extraction and processing for its world-class Las Vegas extraction lab. Specifically, the company is looking into Psilocybin micro-dosing, which, has effects of reducing stress, anxiety and pain without many of the side effects associated with traditional pharmacology products.

“We are evaluating multiple projects that we feel have considerable upside potential that go hand in hand with our existing assets. Both CBD and Psilocybin carry unique and undeniable health benefits,” states David Bentil.

For more information please contact:

### **EGF THERAMED HEALTH CORP.**

Contact: David Bentil, CEO

Email [theramedhealthcorp@gmail.com](mailto:theramedhealthcorp@gmail.com)

Telephone: (778) 559-3939

Website <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

**About EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF)**

EGF Theramed Health Corp. is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company through its subsidiaries has assets and technologies involved in extracting and purifying botanical extracts, creating formulations, and with its medical device technology monitoring capabilities. EGF Theramed's unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated "Natural Products and Herbal Health System" for monitoring, dosing, and recording the effects of natural products on your cardiovascular system.

**DISCLAIMERS**

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on [www.sedar.com](http://www.sedar.com), <https://thecse.com/en/listings/technology/egf-theramed-health-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.



## **EGF THERAMED HEALTH CORP. RAISES \$270,000 IN SECOND TRANCHE OF PRIVATE PLACEMENT**

**Vancouver, B.C., April 29, 2020** – EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “**Company**”) is pleased to announce that it has completed the second tranche of its previously announced (dated April 13, 2020) non-brokered private placement.

The Company has closed on an additional 540,000 units at a price of \$0.50 per unit for gross proceeds of \$270,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to acquire one additional common share of the Company at a price of \$0.75 for a period of 18 months from the closing of the offering. All securities issued in the second tranche offering are subject to a hold period expiring on August 29, 2020.

The net proceeds from the non-brokered private placement are intended to be used for working capital and acquisitions.

The Company has increased its efforts in researching psilocybin and psychedelic extraction and processing for its Las Vegas extraction lab. Specifically, the Company is researching psilocybin micro-dosing and its effects on reducing stress, anxiety and pain without the side effects associated with traditional pharmacology products.

David Bentil, CEO of the Company, stated, “We are evaluating multiple projects that we feel have considerable upside potential that go hand in hand with our existing assets. We believe that CBD and psilocybin carry unique and undeniable health benefits.”

In addition, the Company announces that it intends to grant 175,000 stock options to certain directors of the Company, with each option exercisable at \$1.10 for twenty-four months from the date of issuance.

For more information please contact:

**EGF THERAMED HEALTH CORP.**

Contact: David Bentil, CEO

Email [theramedhealthcorp@gmail.com](mailto:theramedhealthcorp@gmail.com)

Telephone: (778) 559-3939

Website <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

## **About EGF Theramed Health Corp.**

EGF Theramed Health Corp. is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is seeking to be the first company to offer a complete quality assured vertically integrated “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system.

### **DISCLAIMERS**

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the use of funds raised in the private placement, option grant, its research into psilocybin and its mission to become the first company to offer a “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.



## **EGF THERAMED HEALTH CORP. PROVIDES CLARIFICATION ON NEWS RELEASE**

**Vancouver, B.C., April 30, 2020** – EGF THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “**Company**”) further to the news release dated April 29, 2020, the company would like to clarify that all securities issued in the second tranche offering are subject to a hold period expiring on August 30, 2020.

The Company would also like to clarify that the grant of 175,000 stock options to certain directors of the Company, will be exercisable at \$1.00 for twenty-four months from the date of issuance.

For more information please contact:

### **EGF THERAMED HEALTH CORP.**

Contact: David Bentil, CEO

Email [theramedhealthcorp@gmail.com](mailto:theramedhealthcorp@gmail.com)

Telephone: (778) 559-3939

Website <http://www.theramedhealthcorp.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/Theramed-Health-Corporation>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

### **About EGF Theramed Health Corp.**

EGF Theramed Health Corp. is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is seeking to be the first company to offer a complete quality assured vertically integrated “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system.

### **DISCLAIMERS**

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect the use of funds raised in the private placement, option grant, its research into psilocybin and its mission to become the first company to offer a “Natural Products and Herbal Health System” for monitoring, dosing, and recording the effects of natural products on the cardiovascular system. The Company provides forward-looking statements for the purpose of

conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.